Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
International Urology and Nephrology
|
March 5, 2025
The role of non-operative management for high-grade renal injuries
Emily M Kokush, Kunj Jain, John Fastenau, et al.
Cancer Reports (Hoboken, N.J.)
|
February 15, 2022
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies
Rebecca Crawford, Katharine S Gries, Satish Valluri, et al.
British Journal of Haematology
|
February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Vania Hungria, Meral Beksac, Katja C Weisel, et al.
British Journal of Haematology
|
April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Torben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Journal of Cancer Research and Clinical Oncology
|
August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
Saad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.
The Lancet. Haematology
|
November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
Murielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.
American Journal of Hematology
|
January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
Evangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Thomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
BMC Cancer
|
June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
Stefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
International Urology and Nephrology
|
March 5, 2025
The role of non-operative management for high-grade renal injuries
Emily M Kokush, Kunj Jain, John Fastenau, et al.
Cancer Reports (Hoboken, N.J.)
|
February 15, 2022
The patient experience of relapsed refractory multiple myeloma and perspectives on emerging therapies
Rebecca Crawford, Katharine S Gries, Satish Valluri, et al.
British Journal of Haematology
|
February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Vania Hungria, Meral Beksac, Katja C Weisel, et al.
British Journal of Haematology
|
April 6, 2021
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Torben Plesner, Meletios A Dimopoulos, Albert Oriol, et al.
Journal of Cancer Research and Clinical Oncology
|
August 28, 2020
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
Saad Z Usmani, Maria-Victoria Mateos, Vania Hungria, et al.
The Lancet. Haematology
|
November 26, 2020
Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial
Murielle Roussel, Philippe Moreau, Benjamin Hebraud, et al.
American Journal of Hematology
|
January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial
Evangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2020
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Aurore Perrot, Thierry Facon, Torben Plesner, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 5, 2023
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Thomas G Martin, Philippe Moreau, Saad Z Usmani, et al.
BMC Cancer
|
June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial
Stefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Page
of 5